ClinicalTrials.gov
public full text
Public Domain
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
Most of the current antidepressants for major depressive disorder (MDD) are based upon the monoamine hypothesis which cannot fully explain the etiology of depression. NMDA hypofunction has been implicated in the pathophysiology of depression. This study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) in the treatment of antidepressant nonresponders with MDD.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- NMDA Modulation in Major Depressive Disorder in Late- Life#882242
- Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals#862760
- Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)#872259
- Galantamine and CBT4CBT Pilot to Prevent Relapse.#902658
- Gepirone vs Placebo in Treatment of Cocaine Dependence - 3#966195
Record · ID 872089
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive